375 related articles for article (PubMed ID: 8854098)
1. Evaluation of relative promoter strengths of the HIV-1-LTR and a chimeric RSV-LTR in T lymphocytic cells and peripheral blood mononuclear cells: promoters for anti-HIV-1 gene therapies.
Mukhtar M; Duan L; Bagasra O; Pomerantz RJ
Gene Ther; 1996 Aug; 3(8):725-30. PubMed ID: 8854098
[TBL] [Abstract][Full Text] [Related]
2. Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels and is up-regulated by HIV-1 Tat.
Robinson D; Elliott JF; Chang LJ
Gene Ther; 1995 Jun; 2(4):269-78. PubMed ID: 7552987
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell type-specific gene regulation and viral replication.
McAllister JJ; Phillips D; Millhouse S; Conner J; Hogan T; Ross HL; Wigdahl B
Virology; 2000 Sep; 274(2):262-77. PubMed ID: 10964770
[TBL] [Abstract][Full Text] [Related]
4. High expression of exogenous cDNAs directed by HIV-1 long terminal repeat in human cells constitutively producing HIV-1 tat and adenovirus E1A/E1B.
Negrini M; Rimessi P; Sabbioni S; Caputo A; Balboni PG; Gualandri R; Manservigi R; Grossi MP; Barbanti-Brodano G
Biotechniques; 1991 Mar; 10(3):344-53. PubMed ID: 1829615
[TBL] [Abstract][Full Text] [Related]
5. Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression.
Lisziewicz J; Rappaport J; Dhar R
New Biol; 1991 Jan; 3(1):82-9. PubMed ID: 2039768
[TBL] [Abstract][Full Text] [Related]
6. [Study of transactivation effect on transcription by Tat-TAR-system of human immunodeficiency virus type 1 (HIV-1) in non-lymphoid cells HEK293 and Calu-1].
Mingaleeva RN; Chernov IP; Kopantsev EP; Stukacheva EA; Skaptsova NV; Sverdlov ED
Mol Gen Mikrobiol Virusol; 2009; (2):11-5. PubMed ID: 19517804
[TBL] [Abstract][Full Text] [Related]
7. Block of Tat-mediated transactivation of tumor necrosis factor beta gene expression by polymeric-TAR decoys.
Brother MB; Chang HK; Lisziewicz J; Su D; Murty LC; Ensoli B
Virology; 1996 Aug; 222(1):252-6. PubMed ID: 8806505
[TBL] [Abstract][Full Text] [Related]
8. Drastic decrease of transcription activity due to hypermutated long terminal repeat (LTR) region in different HIV-1 subtypes and recombinants.
de Arellano ER; Alcamí J; López M; Soriano V; Holguín A
Antiviral Res; 2010 Nov; 88(2):152-9. PubMed ID: 20713090
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional activation of minimal HIV-1 promoter by ORF-1 protein expressed from the SalI-L fragment of human herpesvirus 6.
Kashanchi F; Thompson J; Sadaie MR; Doniger J; Duvall J; Brady JN; Rosenthal LJ
Virology; 1994 May; 201(1):95-106. PubMed ID: 8178493
[TBL] [Abstract][Full Text] [Related]
10. Interactions between Marek's disease virus encoded or induced factors and the Rous sarcoma virus long terminal repeat promoter.
Banders UT; Coussens PM
Virology; 1994 Feb; 199(1):1-10. PubMed ID: 8116231
[TBL] [Abstract][Full Text] [Related]
11. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.
Jayan GC; Cordelier P; Patel C; BouHamdan M; Johnson RP; Lisziewicz J; Pomerantz RJ; Strayer DS
Gene Ther; 2001 Jul; 8(13):1033-42. PubMed ID: 11438838
[TBL] [Abstract][Full Text] [Related]
12. Use of cis- and trans-acting viral regulatory sequences to improve expression of human immunodeficiency virus vectors in human lymphocytes.
Parolin C; Taddeo B; Palú G; Sodroski J
Virology; 1996 Aug; 222(2):415-22. PubMed ID: 8806525
[TBL] [Abstract][Full Text] [Related]
13. Requirement of the human immunodeficiency virus type 1 env gene sequence for TAR-independent trans activation by Tat from the major immediate-early promoter of murine cytomegalovirus.
Kim YS
Biochem Biophys Res Commun; 1994 Sep; 203(2):1152-9. PubMed ID: 8093034
[TBL] [Abstract][Full Text] [Related]
14. Ribozyme targeting of HIV-1 LTR.
Ventura M; Wang P; Franck N; Saragosti S
Biochem Biophys Res Commun; 1994 Sep; 203(2):889-98. PubMed ID: 8093072
[TBL] [Abstract][Full Text] [Related]
15. Bovine immunodeficiency virus tat gene: cloning of two distinct cDNAs and identification, characterization, and immunolocalization of the tat gene products.
Fong SE; Greenwood JD; Williamson JC; Derse D; Pallansch LA; Copeland T; Rasmussen L; Mentzer A; Nagashima K; Tobin G; Gonda MA
Virology; 1997 Jul; 233(2):339-57. PubMed ID: 9217057
[TBL] [Abstract][Full Text] [Related]
16. Retinoblastoma gene inhibits transactivation of HIV-LTR linked gene expression upon co-transfection in He La cells.
Prasad MV; Shanmugam G
Biochem Mol Biol Int; 1993 Jan; 29(1):57-62. PubMed ID: 8490568
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs.
Kashanchi F; Sadaie MR; Brady JN
Virology; 1997 Jan; 227(2):431-8. PubMed ID: 9018142
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the basal-level activity of HIV-1 long terminal repeat by HIV-1 nucleocapsid protein.
Zhang JL; Sharma PL; Crumpacker CS
Virology; 2000 Mar; 268(2):251-63. PubMed ID: 10704334
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.
Scala G; Quinto I; Ruocco MR; Mallardo M; Ambrosino C; Squitieri B; Tassone P; Venuta S
J Virol; 1993 May; 67(5):2853-61. PubMed ID: 8386279
[TBL] [Abstract][Full Text] [Related]
20. Transduction of the human immunodeficiency virus type 1 promoter into human chromosomal DNA by adeno-associated virus: effects on promoter activity.
Nahreini P; Mathews MB
Virology; 1997 Jul; 234(1):42-50. PubMed ID: 9234945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
